Progress in Research on the Effects of Platelet-Rich Plasma Ovarian Injection on Early Ovarian Reserve Dysfunction and Premature Ovarian Insufficiency
March 2026
in “
Journal of Ovarian Research
”
Studysummary This review explores the potential of platelet-rich plasma therapy for early ovarian reserve decline and premature ovarian insufficiency, indicating some ovarian function improvements in initial studies but highlighting the need for further research.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document explores the potential of Platelet-Rich Plasma (PRP) as a regenerative therapy for early ovarian reserve dysfunction (EORD) and premature ovarian insufficiency (POI) in women under 40. PRP, rich in growth factors, may improve ovarian function by enhancing angiogenesis, reducing oxidative stress, and inhibiting apoptosis, potentially activating dormant follicles and improving fertility outcomes. However, variability in PRP preparation and lack of standardization pose challenges for clinical application. Clinical studies show mixed results, and while PRP is generally safe, long-term safety data are limited. The document highlights the need for standardized protocols and larger randomized controlled trials to confirm efficacy and optimize treatment strategies.
